On May 23, 2011, the U.S. Judicial Panel on Multidistrict
Litigation (“JPML”) ordered that all federal Fosamax femur fracture lawsuits be
consolidated and centralized in the U.S. District Court for the District of New
Jersey and assigned to the Honorable Garrett E. Brown, Jr. Last week, the JPML convened at the Gene
Snyder U.S. Courthouse in
Recently, Fosamax and similar medications have been the subject of increased scrutiny as numerous studies release findings which substantiate that there is, in fact, a link between Fosamax use and atypical femur fractures. On October 13, 2010 the U.S. Food and Drug Administration (“FDA”) issued a warning that bisphosphonates put patients at risk for atypical thigh bone (femur) fractures. In addition to issuing that warning, the FDA required bisphosphonate manufacturers to change the drugs’ labeling.
Fosamax Femur Fracture MDL
In reaching its decision to grant Merck’s request and form a
Fosamax femur fracture MDL, the JPML determined
that there were common questions of fact to warrant the transfer of pending
federal Fosamax femur fracture lawsuits to one federal district court for
coordinated and consolidated pre-trial proceedings. The panel determined that the District of New
Jersey was the appropriate forum for the Fosamax femur fracture MDL because
most of the federal cases are currently pending there, Merck is headquartered
in
Bernstein Liebhard LLP is actively investigating and litigating cases on behalf of clients who have suffered a Fosamax femur fracture. Bernstein Liebhard LLP has provided a wealth of consumer information concerning the risks associated with Fosamax use on its website, www.consumerinjurylawyers.com. If you or a loved one took Fosamax and sustained a femur fracture, you may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries.
For more information about filing a Fosamax lawsuit, contact an attorney at Bernstein Liebhard LLP at (877) 779-1414 or at info@consumerinjurylawyers.com.
Bernstein Liebhard LLP